SGX Medical
Bloomington, Illinois, 61704, United States
NCT Number: NCT04466111
This is a post-market, open-label, prospective, multi-center, observational study evaluating upper limb pain relief with the DTM™ SCS programming approach.
Data at follow-up visits will be compared to baseline assessments collected at the beginning of the study.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Bloomington, Illinois, 61704, United States
This is a post-market, open-label, prospective, multi-center, observational study evaluating upper limb pain relief with the DTM™ SCS programming approach.
Data at follow-up visits will be compared to baseline assessments collected at the beginning of the study.
The expected total duration of this study is approximately 26 months. Enrollment of participants is expected to last 20 months. Participants that have received the permanent implant will be followed up for 12 months after their device has been activated. A participant will likely be committed to the study for about 14 months. This consists of Baseline assessments, up to 10 days of trial stimulation, and 12 months of treatment following implantation and activation of the device. All subjects who plan on remaining implanted through the 6-month visit or who have completed their 6-month visit will be offered to return for an additional 12-month visit. This would increase their commitment to the study to 14 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The study will use the commercially available IntellisTM neurostimulator and compatible SCS system components from Medtronic using stimulation parameters within the specifications approved for use in the approved indications. The study will stimulate the cervical dorsal columns of the spinal cord.
Other names: Spinal Cord Stimulation (SCS) device system
Time frame: 3 months
The primary efficacy endpoint is the percentage of implanted subjects who respond to DTM SCS therapy at 3-months after device activation. An individual responder is a subject that experiences at least a 50% decrease in upper limb pain relative to baseline assessment.
SGX Procura LLC
Industry
A Post-Market, Observational Clinical Study to Evaluate the Effects of Differential Target Multiplexed DTM™ SCS Programming in Treating Intractable Chronic Upper Extremity Limb Pain
Acronym: PROC2020PM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05983822
Brain Diseases, Cardiovascular Diseases
Roma, RM, Italy
View Trial DetailsNCT04043234
Amputation, Upper Limb
Silver Spring, Maryland, United States
View Trial DetailsNCT06539936
Amputation, Upper Limb
Redondo Beach, California, United States
View Trial DetailsNCT05888428
Amputation, Upper Limb
Grand Rapids, Michigan, United States
View Trial Details